ensysce.com (ENSC): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The market capitalization trend for Ensysce Biosciences (ENSC) reflects an EV/EBITDA value of 0.00, while patent protection for TAAP and MPAR systems creates significant barriers to entry for competitors. The business is based on developing unique methods for combating opioid addiction, ensuring technological superiority within the industry. Developments regarding gastrointestinal drug safety are constrained by strict regulatory oversight and the high cost of FDA certification.

ENSC Ensysce Biosciences, Inc.: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/10/2026

ensysce.com - analytical breakdowns and key metrics (ENSC)

- current price and projected stock value:

Stock Price Ensysce Biosciences, Inc.|ENSC - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Ensysce Biosciences, Inc.|ENSC - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Ensysce Biosciences|ENSC - Company Net Assets|Market Capitalization to Book Value Ratio ensysce.com|ENSC - Company Assets

- debt and solvency information:

- business earnings and investment ratios data:

ENSC - Net Income|Projected Future Earnings Ensysce Biosciences|ENSC - Market Cap to Earnings|Projected Price to Earnings Ensysce Biosciences, Inc.|ENSC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Ensysce Biosciences, Inc.|ENSC - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Ensysce Biosciences|ENSC - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months ensysce.com|ENSC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Ensysce Biosciences

Comprehensive company analysis:Ensysce (ENSC)

Original product of Ensysce Biosciences, Inc.

Ensysce Biosciences (ENSC) is developing an innovative patent portfolio to combat opioid addiction with the support of US government institutions. The EV/EBITDA multiple on the GURU.Markets chart compares the total enterprise value, including net debt, against operating profit before taxes. This price action allows investors to assess the real value of assets and the capital stability of Ensysce Biosciences (ENSC) amid a high debt load.

Competitor analysis

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|ACHV (Achieve Life Sciences, Inc) - EV/EBITDA Multiple|Company Value to EBITDA skyebioscience.com SKYE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anebulo Pharmaceuticals (ANEB)|intercure.co - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nutriband NTRB|Total Company Value to Operating Income Before Depreciation Ratio Nasus Pharma Ltd. (NSRX)|IGC: Enterprise Value to EBITDA Ratio|Company Value to EBITDA MIRA Pharmaceuticals|Flora Growth Corp. (FLGC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IMCC - Total Company Value to Operating Income Before Depreciation Ratio|ADIL (Adial Pharmaceuticals Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Artelo (ARTL)|EV/EBITDA Multiple TTNP|GNLN - Company Value to EBITDA|InMed Pharmaceuticals - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation AKAN|Enveric Biosciences, Inc. - EV/EBITDA Multiple|BGXX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HPCO: EV/EBITDA Multiple